Opdivo combines Yervoy (ipilimumab) first-line treatment for high-risk advanced renal cell carcinoma to be approved by Taiwan

Recently, Japanese drugmaker OnoPharmaceutical
series(OPTW) has received theof Taiwan's Taiwan ese fooddrug (T
FDA(t.
Chinese: Odivo, generic name: Navuriu monoantigen, nivolumab) supplement, approved Opdivo joint Yervoy (ipilimumab) first-line treatment of high-risk advanced renal cell carcinoma (RCC) patientsOpdivo and Yervoy
Opdivo and Yervoy are both tumor immunotherapy, which uses the body's own immune system to fight tumors through different regulatory elements in the targeting immune system, where Opdivo targets blocking the PD-1/PD-L1 pathway and Yervoy targets blocking CTLA-4particularly noteworthy, Both Opdivo and Yervoy are immunotherapy at the Nobel prize levelOn October 1st, the 2018 Nobel Prize in Physiology or Medicine was announced, and two immunologists (Professor James PAllison of the University of Texas and Professor Tasuku Honjo of Kyoto University in Japan) were awarded for the discovery of cancer therapies that inhibit negative immunomodulation, the former found immuno-checkpoint therapy for CTLA-4, and the latter found immuno-checkpoint therapy for PD-1on Ono Pharmaceuticals Ono Pharmaceuticals, the original developer of Opdivo, a partnership with Boxei Meishi's Guibao in 2011 to authorize the development and commercialization rights of Peridomie Squibb, except in Japan, South Korea, and Taiwan, China In July 2014, the two sides further expanded their strategic cooperation to develop and commercialize a variety of immunotherapies (including monotherapy and combination therapies) for cancer patients in Japan, South Korea and Taiwan